Global /United States /Healthcare /Drug Manufacturers - General /LENZ

LENZ Therapeutics, Inc.

LENZ

• NASDAQ: LENZ • Delayed

9.05USD -2.6%

As of 14 June 2026, LENZ Therapeutics, Inc. has a market cap of $283.76M USD, ranking #18918 globally and #3148 in the United States. It ranks #1707 in the Healthcare sector, and #624 in the Drug Manufacturers - General industry.

Global Rank

18918

Country Rank

3148

Sector Rank

1707

Industry Rank

624

Key Stats

Market Cap

$283.76MUSD

Enterprise Value

-$7.77MUSD

Revenue (TTM)

$19.09MUSD

EBITDA (TTM)

-$90.85MUSD

Net Income (TTM)

-$82.13MUSD

PS Ratio

14.9

PB Ratio

1.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Evert Schimmelpennink open_in_new

Employees

152

Founded

2019

IPO

25 Jun 2021

Website

lenz-tx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.6%	-9.5%	7.6%	-52%	-71%	-44%	-67%	-67%	-96%

News

LENZ Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	LENZ LENZ Therapeutics Inc ISIN: US52635N1037 Shares Out.: Shares Outstanding: 31.354M¹ Shares Float: 27.359M² TV: TradingView: NASDAQ: LENZ SA: Stock Analysis: NASDAQ: LENZ YF: Yahoo Finance: LENZ GF: Google Finance: NASDAQ: LENZ NQ: NASDAQ: LENZ BA: Barron's: LENZ MS: Morningstar: XNAS: LENZ	9.05 USD	TV: TradingView: NASDAQ: LENZ SA: Stock Analysis: NASDAQ: LENZ YF: Yahoo Finance: LENZ GF: Google Finance: NASDAQ: LENZ NQ: NASDAQ: LENZ BA: Barron's: LENZ MS: Morningstar: XNAS: LENZ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 268K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 193K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 127K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 96K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 53K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 41K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 113K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 102K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 97K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 64K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 39K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 38K%	14.6	United Kingdom

chevron_leftBack